Will the average out-of-pocket cost for Zepbound for CVS Caremark members with commercial insurance decrease by at least 10% by March 31, 2027?

While coverage is restored, the actual cost to patients remains a key factor in access. This question examines whether increased coverage and potential competition will lead to a tangible reduction in patient costs for Zepbound. The resolution will be based on publicly available data or CVS Caremark's official statements regarding average patient costs.

Implied probability (Yes)

40%

Closes

2029-08-26